Top 10 Challenges in Cancer Immunotherapy

• Published in: Immunity (Cambridge, Mass.) Vol. 52; no. 1; pp. 17 - 35
• Main Authors: Hegde, Priti S., Chen, Daniel S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.01.2020; Elsevier Limited
• Subjects: adaptive immune resistance; Antigens; Biology; biomarkers; bispecific antibodies; Cancer; cancer immune phenotypes; Cancer immunotherapy; CAR T; cellular therapy; Clinical trials; Collaboration; Cytotoxicity; Drug dosages; Humans; Immune system; immuno-oncology; Immunology; Immunotherapy; Immunotherapy - methods; intrinsic immune resistance; Models, Biological; Mutation; Neoplasms - genetics; Neoplasms - immunology; Neoplasms - therapy; Patients; primary immune escape; secondary immune escape; synthetic immunity; T cell engagers; Tumor Microenvironment - immunology; tumor mutational burden; Tumors; intrinsic immune resistance; biomarkers; CAR T; adaptive immune resistance; cellular therapy; primary immune escape; cancer immune phenotypes; tumor mutational burden; secondary immune escape; cancer immunotherapy; synthetic immunity; T cell engagers; immuno-oncology; bispecific antibodies

Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define...